The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

For decades, scientists have puzzled over why smoking makes Crohn’s disease worse but seems to protect people from ulcerative ...

On a population basis, a study published this month shows prevalence is now 254.8 cases of ulcerative colitis and 77.0 cases ...

Phase 3 data showed comparable safety and efficacy of subcutaneous and intravenous induction regimens of guselkumab for ...

Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA ...

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous ...